KW-0761 (Mogamulizumab)

mogamulizumab · Kyowa Kirin Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KW-0761 (Mogamulizumab), covering 2024-06-17 to 2024-06-17. Get the full timeline:

Most recent: Clinical Trial Update: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) [Phase 2]